by rss feed | Jun 21, 2025 | Diabetes, News Feeds, stem cells for diabetes, Vertex diabetes, Zimislecel
In groundbreaking results, Vertex Pharmaceuticals presented and published results showing that ten out of twelve patients in a small trial exhibited signs of a cure for their type 1 diabetes after receiving the stem cell therapy Zimislecel. This is extremely exciting....
by rss feed | Sep 29, 2024 | Deja you, Diabetes, Hongkui Deng, human cloning, News Feeds, stem cells for diabetes
People often ask me what is the most promising new cell therapy and while it is difficult to choose just one, I often highlight the promise of stem cells for diabetes. Here in the U.S., early data from diabetes clinical trials by Vertex look encouraging. Other teams...
by rss feed | Mar 3, 2024 | Diabetes, News Feeds, Vertex, weekly reads
Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space...
by rss feed | Mar 3, 2024 | Diabetes, News Feeds, Vertex, weekly reads
Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space...
by rss feed | Jan 4, 2022 | Diabetes, News Feeds, Predictions, Vertex, ViaCyte
The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past...
by rss feed | Oct 19, 2021 | Diabetes, News Feeds, Vertex
It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant....
